Article in Molecular cancer research : MCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
30 authors at 9 institutions in 5 countries.
Hongxia Chen *Department of Hematology, Chongqing University Three Gorges Hospital, Chongqing, China.ORCID 0000-0003-1415-0950
Yunpeng Bai *Department of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-5879-3555
Michihiro KobayashiDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0001-6065-6026
Shiyu XiaoDepartment of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-1175-6845
Sergio BarajasDepartment of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0003-2190-8280
Wenjie CaiDepartment of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-5352-8779
Sisi ChenDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0003-3250-5727
Jinmin MiaoDepartment of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-7471-0847
Frederick Nguele MekeDepartment of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-8542-0343
Chonghua YaoDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0009-0008-9279-3410
Yuxia YangDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0001-7966-7809
Katherine StrubeDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0009-0000-1607-1530
Odelia SatchiviDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0009-0008-5199-2333
Jianmin SunDivision of Translational Cancer Research and Lund Stem Cell Center, Lund University, Lund, Sweden.ORCID 0000-0003-2327-4285
Lars RönnstrandDivision of Translational Cancer Research and Lund Stem Cell Center, Lund University, Lund, Sweden.ORCID 0000-0003-1275-5809
James M CroopDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0009-0002-3109-7127
H Scott BoswellDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0009-0004-8444-6727
Yuzhi JiaDepartment of Pharmacology, Northwestern University, Chicago, Illinois.ORCID 0000-0002-6534-0036
Huiping LiuDepartment of Pharmacology, Northwestern University, Chicago, Illinois.ORCID 0000-0003-4822-7995
Loretta S LiRobert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.ORCID 0000-0002-3018-597X
Jessica K AltmanDepartment of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0003-1987-1896
Elizabeth A EklundDepartment of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-8578-6027
Madina SukhanovaDepartment of Pathology, Northwestern University, Chicago, Illinois.ORCID 0000-0002-1843-7038
Wei TongChildren's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0001-9951-2273
Hamid BandDepartment of Genetics, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-4996-9002
Danny T HuangCancer Research UK Beatson Institute and Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-6192-259X
Leonidas C PlataniasDepartment of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-9740-7573
Zhong-Yin ZhangDepartment of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-5527-7910
Northwestern University · USIndiana University – Purdue University Indianapolis · USPurdue University West Lafayette · USLund University · SECancer Research UK Scotland Institute · GBChildren's Hospital of Philadelphia · USNebraska Medical Center · USPeking University · CNShanghai Traditional Chinese Medicine Hospital · CN
Funding
Structure/Function of Protein Tyrosine PhosphatasesR01CA069202 · NCI · YESHIVA UNIVERSITY · PI Zhong-Yin Zhang · 1996 to 2026
$7.3M
Molecular mechanism underlying clonal expansion of hematopoietic stem cellsR01HL150624 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Yan Liu · 2019 to 2026
$3.8M
Regulation of Ribosome Biogenesis in Hematopoietic Stem CellsR01DK127738 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI TONG, WEI · 2020 to 2024
$3.0M
Novel Regulation of Oncogenic NRAS Signaling in Myeloid MalignanciesR01CA271523 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Wei Tong · 2022 to 2026
$2.7M
Regulation of FLT3 Signaling in LeukemiaR01CA282668 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Wei Tong · 2023 to 2026
$2.5M
Mutant p53 rejuvenates aged stem cells through modulating epigenetic regulatorsR56AG052501 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIU, YAN · 2017 to 2017
$255k
Molecular mechanisms underlying clonal expansion of hematopoietic stem cellsR56DK119524 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI LIU, YAN · 2018 to 2018
$150k
Mutant p53 in pathogenesis of Myelodysplastic SyndromesF31HL160120 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BARAJAS, SERGIO · 2021 to 2024
$129k
Cancer Research UK 29256Department of Defense W81XWH-18–1-0265Department of Defense W81XWH-19–1-0575NCI NIH HHS R01 CA069202NCI NIH HHS R01 CA271523NCI NIH HHS R01 CA282668NHLBI NIH HHS F31 HL160120NHLBI NIH HHS R01 HL150624NIA NIH HHS R56 AG052501NIDDK NIH HHS R01 DK127738NIDDK NIH HHS R56 DK119524
6 · The paper itself
Abstract
Receptor tyrosine kinase KIT is frequently activated in acute myeloid leukemia (AML). While high PRL2 (PTP4A2) expression is correlated with activation of SCF/KIT signaling in AML, the underlying mechanisms are not fully understood. We discovered that inhibition of PRL2 significantly reduces the burden of oncogenic KIT-driven leukemia and extends leukemic mice survival. PRL2 enhances oncogenic KIT signaling in leukemia cells, promoting their proliferation and survival. We found that PRL2 dephosphorylates CBL at tyrosine 371 and inhibits its activity toward KIT, leading to decreased KIT ubiquitination and enhanced AKT and ERK signaling in leukemia cells. IMPLICATIONS: Our studies uncover a novel mechanism that fine-tunes oncogenic KIT signaling in leukemia cells and will likely identify PRL2 as a novel therapeutic target in AML with KIT mutations.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation. · full record | OpenQuestion